PCN163 IMPROVEMENT OF THE INNOVATION & VALUE INITIATIVE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR NON-SMALL-CELL LUNG CANCER BASED ON PUBLIC FEEDBACK

Abstract

In January 2019, the Innovation & Value Initiative presented a flexible open-source simulation model for EGFR+ non-small-cell lung cancer (NSCLC). Our aim was to collect feedback on this initial version of the model to set priorities for the development of the next model iteration. Following the public release of the model, we invited feedback and suggestions for improvements during a public comment period (January 2019 – April 2019). Subsequently, a panel of subject matter experts (n=5; patient, oncologists, and methodologists) determined which of the received suggestions should be implemented by means of a modified Delphi process. Two rounds of surveys were administered using a web-based survey tool. Panel surveys focused on improvements that either require substantial resources to implement (such as elaborate programming or additional evidence collection) or are likely to have a substantial impact on the findings of model analysis. A total of 98 comments were received. These suggestions related to: the incorporation of additional patient characteristics; palliative care; mechanism of treatment resistance; adverse events; model output; elements of value; addition or removal of specific treatment combinations; impact of prior treatment on future treatment efficacy; and estimation of preference weights for the multi-criteria decision analysis (MCDA) module. The Delphi survey covered 28 items and the following were ranked as most important to include in the next model iteration: add nausea, vomiting, and immune-related adverse events; add out of pocket costs and probability of unemployment; elicit preference weights for the MCDA; and provide output by line of treatment in addition to the total sequence. The current study illustrates areas of improvement for the IVI-NSCLC model based on public feedback. Version 2 of the model is planned to be released in early 2021.